Summary Statement Information

Shown in the summary statement are a priority score and a percentile ranking, if applicable. For the most part, only R01 and R21applications receive a percentile ranking. The priority score is determined by averaging the scores given individually and privately by each voting member of the study section. The priority score scale ranges from 100 to 500, with 100 representing the highest scientific merit. The percentile ranking reflects the relative standing of your application among all those evaluated by the study section for this and the previous two meetings. All scored applications will also be forwarded to the next meeting of the National Cancer Advisory Board (NCAB) (http://deainfo.nci.nih.gov/advisory/ncab.htm).

If your application is selected for funding, you will be contacted by NCI staff. The dollar level of the award may be reduced from the study section's recommended direct costs as a result of fiscal constraints within the NCI or further staff evaluation. If your application is not selected for funding, you will not be formally notified. However, you can contact your Program Director at any time with questions about your summary statement or to discuss options that may be available to you. Your Program Director's name, phone number, and email address are located in the upper left hand corner of the first page of the summary statement. Any official review appeals must be filed no later than 30 calendar days following the above NCAB meeting.

The Division of Cancer Biology is dedicated to providing a high level of program support to the scientific community. Should you feel the need for recourse, you are welcome to contact the Division Ombudsman, Dr. Dan Gallahan, by telephone at (301) 496-8636 or e-mail at dg13w@nih.gov.